IBDEI1JS ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24740,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,24740,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,24740,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,24741,0)
 ;;=C92.50^^107^1211^14
 ;;^UTILITY(U,$J,358.3,24741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24741,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,24741,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,24741,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,24742,0)
 ;;=C94.40^^107^1211^17
 ;;^UTILITY(U,$J,358.3,24742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24742,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,24742,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,24742,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,24743,0)
 ;;=C94.42^^107^1211^15
 ;;^UTILITY(U,$J,358.3,24743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24743,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,24743,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,24743,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,24744,0)
 ;;=C94.41^^107^1211^16
 ;;^UTILITY(U,$J,358.3,24744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24744,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,24744,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,24744,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,24745,0)
 ;;=D62.^^107^1211^18
 ;;^UTILITY(U,$J,358.3,24745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24745,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,24745,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,24745,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,24746,0)
 ;;=C92.41^^107^1211^19
 ;;^UTILITY(U,$J,358.3,24746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24746,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,24746,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,24746,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,24747,0)
 ;;=C92.40^^107^1211^20
 ;;^UTILITY(U,$J,358.3,24747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24747,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,24747,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,24747,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,24748,0)
 ;;=D56.0^^107^1211^21
 ;;^UTILITY(U,$J,358.3,24748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24748,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,24748,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,24748,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,24749,0)
 ;;=D63.1^^107^1211^23
 ;;^UTILITY(U,$J,358.3,24749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24749,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,24749,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,24749,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,24750,0)
 ;;=D63.0^^107^1211^24
 ;;^UTILITY(U,$J,358.3,24750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24750,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,24750,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,24750,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,24751,0)
 ;;=D63.8^^107^1211^22
 ;;^UTILITY(U,$J,358.3,24751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24751,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,24751,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,24751,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,24752,0)
 ;;=C22.3^^107^1211^27
